Animal models for COVID-19,Nature

当前位置： X-MOL 学术 › Nature › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Animal models for COVID-19
Nature ( IF 50.5 ) Pub Date : 2020-09-23 , DOI: 10.1038/s41586-020-2787-6
César Muñoz-Fontela _{1,

2} , William E Dowling ₃ , Simon G P Funnell ₄ , Pierre-S Gsell ₅ , A Ximena Riveros-Balta ₅ , Randy A Albrecht ₆ , Hanne Andersen ₇ , Ralph S Baric ₈ , Miles W Carroll ₄ , Marco Cavaleri ₉ , Chuan Qin ₁₀ , Ian Crozier ₁₁ , Kai Dallmeier ₁₂ , Leon de Waal ₁₃ , Emmie de Wit ₁₄ , Leen Delang ₁₂ , Erik Dohm ₁₅ , W Paul Duprex ₁₆ , Darryl Falzarano ₁₇ , Courtney L Finch ₁₈ , Matthew B Frieman ₁₉ , Barney S Graham ₂₀ , Lisa E Gralinski ₈ , Kate Guilfoyle ₁₃ , Bart L Haagmans ₂₁ , Geraldine A Hamilton ₂₂ , Amy L Hartman ₁₆ , Sander Herfst ₂₁ , Suzanne J F Kaptein ₁₂ , William B Klimstra ₂₃ , Ivana Knezevic ₅ , Philip R Krause ₂₄ , Jens H Kuhn ₁₈ , Roger Le Grand ₂₅ , Mark G Lewis ₇ , Wen-Chun Liu ₆ , Pauline Maisonnasse ₂₅ , Anita K McElroy ₂₆ , Vincent Munster ₁₄ , Nadia Oreshkova ₂₇ , Angela L Rasmussen ₂₈ , Joana Rocha-Pereira ₁₂ , Barry Rockx ₂₁ , Estefanía Rodríguez _{1,

2} , Thomas F Rogers ₂₉ , Francisco J Salguero ₄ , Michael Schotsaert ₆ , Koert J Stittelaar ₁₃ , Hendrik Jan Thibaut ₁₂ , Chien-Te Tseng ₃₀ , Júlia Vergara-Alert ₃₁ , Martin Beer ₃₂ , Trevor Brasel ₃₀ , Jasper F W Chan ₃₃ , Adolfo García-Sastre ₆ , Johan Neyts ₁₂ , Stanley Perlman ₃₄ , Douglas S Reed ₂₃ , Juergen A Richt ₃₅ , Chad J Roy ₃₆ , Joaquim Segalés _{31,

37} , Seshadri S Vasan _{38,

39} , Ana María Henao-Restrepo ₅ , Dan H Barouch ₄₀

Affiliation

Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
German Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
Centre for Epidemic Preparedness Innovations (CEPI), Washington, DC, USA.
National Infection Service, Public Health England, Salisbury, UK.
World Health Organization, Geneva, Switzerland.
Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bioqual Inc, Rockville, MD, USA.
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
European Medicines Agency, Amsterdam, The Netherlands.
Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, China.
Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Viroclinics Xplore, Schaijk, The Netherlands.
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Animal Resources Program, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Microbiology and Molecular Genetics, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
VIDO-Intervac, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.
Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
Emulate Inc, Boston, MA, USA.
Department of Immunology, Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA.
Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Inserm, CEA, Université Paris-Saclay, Paris, France.
Division of Pediatric Infectious Diseases, Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Wageningen Bioveterinary Research (WBVR), Wageningen University and Research, Lelystad, The Netherlands.
Center for Infection and Immunity, Columbia Mailman |School of Public Health, New York, NY, USA.
Division of Infectious Diseases, University of California San Diego, San Diego, CA, USA.
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus Universitat Autònoma de Barcelona, Bellaterra, Spain.
Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA.
Tulane National Primate Research Center, Covington, LA, USA.
Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, Bellaterra, Spain.
Australian Centre for Disease Preparedness, CSIRO, Geelong, Victoria, Australia.
Department of Health Sciences, University of York, York, UK.
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19. The findings of a World Health Organization expert working group that is developing animal models to test vaccines and therapeutic agents for the treatment of COVID-19, and their relevance for preclinical testing, are reviewed.

更新日期：2020-09-23

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11